agilon health (AGL) Q1 2026 earnings review
Profit Over Growth: The 'Addition by Subtraction' Strategy Works
agilon health is proving that shedding empty revenue can rapidly repair a damaged balance sheet. After a disastrous 2025 plagued by runaway medical costs and poor risk adjustment visibility, the company purposefully shrank its total member base by 11% YoY, prioritizing contract profitability over sheer volume. The result is a textbook reversing trend: while Total Revenue fell 7%, Adjusted EBITDA rocketed 162% to $54 million. This stark divergence—lower top line, vastly improved bottom line—validates the painful turnaround initiated by interim leadership. Armed with an upgraded full-year guidance and a new permanent CEO, agilon is stabilizing, though investors must still watch elevated medical cost trends closely.
🐂 Bull Case
Gross Profit jumped 28% and Medical Margin grew 16% YoY, proving that renegotiating or exiting unprofitable payer contracts is successfully trapping cash that previously leaked to cover high medical utilization.
Management confidently raised FY26 Adjusted EBITDA guidance from a midpoint of $0 to $25M. This signals that their new data pipelines are finally accurately capturing member risk scores (+1.5% net of v28 model changes).
🐻 Bear Case
agilon reserved a 7.4% medical cost trend for its Medicare Advantage members in Q1. While prudent, this highlights that the macroeconomic environment for senior healthcare utilization remains aggressively high.
Total membership on the platform is down 11% YoY to 536,000. While intentional to fix profitability, the company will eventually need to prove it can acquire new, profitable members to scale.
⚖️ Verdict: 🟢
Bullish. It is rare to see a healthcare turnaround take root this quickly. Slashing unprofitable members to drive a 162% spike in Adjusted EBITDA is high-quality execution. The guidance raise confirms the worst of the 2025 crisis is in the rearview mirror.
Key Themes
Pruning the Portfolio Delivers Immediate Margin Yield
The central narrative of Q1 is the successful execution of agilon's contract discipline. By walking away from unprofitable Medicare Advantage agreements (shedding roughly 65,000 MA members YoY), the company drastically improved unit economics. Medical margin expanded from $128M to $149M, confirming that the remaining member pool is fundamentally healthier for the bottom line.
ACO REACH Outperformance Stabilizes Earnings
agilon's unconsolidated ACO REACH entities continue to act as a crucial ballast. The ACO model entities contributed $27M to Adjusted EBITDA in Q1 (up from $20M last year). Based on this momentum, management raised the expected FY26 EBITDA contribution from these models to $25-$30M.
Enhanced Data Platform Proves Its Worth
The massive prior-period development (PPD) hits of 2025 were caused by poor visibility into patient claims. The investments into a new clinical data pipeline are showing early returns: the company successfully secured an expected YoY member risk score increase of 1.5% (net of CMS v28 model headwinds), allowing them to price and reserve accurately.
Elevated Medical Cost Trends (Macro Headwind)
Despite better margins, the macroeconomic utilization environment remains punishing. agilon explicitly noted they are reserving medical cost trends for MA members at 7.4%. While this conservatism is welcome given 2025's forecasting failures, a 7+ percent ongoing trend will consistently pressure gross margins if payer bids or risk adjustment scores falter.
Contradictory Expense: Geography Entry Costs
The company's primary strategy has been profitability over growth, evidenced by an 11% drop in total members and market exits. Yet, agilon is still modeling $15M in Geography Entry Costs for FY26 (including $2M spent in Q1). Plowing capital into new geography expansion while simultaneously shrinking the core active network introduces execution risk and drags on near-term EBITDA.
Leadership Stability Secured
Tim O'Rourke joins as permanent CEO, succeeding interim Executive Chairman Ron Williams. O'Rourke's arrival marks the transition from 'crisis turnaround' to normalized operations. Investors will look to O'Rourke to re-establish a profitable growth trajectory now that the bleeding has been stopped.
Other KPIs
Accelerating significantly. Up 28% YoY from $51 million in 25Q1, despite the 7% drag in total top-line revenue. This clearly illustrates improved contract economics and a healthier overall risk pool.
Stable. Compares favorably against a very manageable total debt load of $32 million. The company has successfully insulated its balance sheet during the transition, ensuring they do not need to tap hostile capital markets to fund the remainder of the turnaround.
Guidance
Reversing. Upgraded from the previous ($15M) to $15M range. This implies a massive reversal from the ~$296 million loss posted in FY25. Driven by higher member risk scores, new full-risk contracts, and steady ACO REACH performance.
Accelerating. Raised from the prior $300M - $350M forecast. The increase reflects early success in 2026 contracting and relief from exited underperforming markets.
Stable. The midpoint of $1.45B suggests flat sequential progression from Q1 2026 ($1.42B), reflecting the stabilized, pruned membership base.
Decelerating sequentially. Expected to step down from the $54M generated in Q1. This is normal seasonality in Medicare Advantage, where Q1 tends to be highly profitable before utilization builds throughout the calendar year.
Key Questions
Returning to Growth
Now that the unprofitable contracts have been purged and margins are recovering, what is the timeline and strategy for returning to net positive membership growth without sacrificing unit economics?
Medical Cost Trend Durability
You reserved at a 7.4% medical cost trend in Q1. Do you view this elevated rate as the permanent 'new normal' for the senior population, or do you see structural reasons it will moderate in late 2026/2027?
Geography Entry Spend
With total membership shrinking by double digits YoY, what is the strategic rationale behind continuing to spend $15M on Geography Entry Costs this year rather than letting those dollars drop to the bottom line?